




# The Leading dd-cfDNA Test for Kidney Transplant Patients

Trusted by over 80% of US Transplant Centers by Volume


Barbara P., kidney transplant recipient

## Current Surveillance Options Have Limitations

### Serum Creatinine Can Be a Delayed Marker of Graft Injury



The DART clinical trial showed that serum creatinine was unable to distinguish between active rejection and no active rejection.<sup>1</sup>



It also showed that AlloSure results distinguished between the presence and absence of rejection.


## AlloSure is a Simple Blood Test for Kidney Transplant Health

### What is AlloSure?

Developed specifically for transplant patients, AlloSure is a blood test that analyzes SNPs selected across all 22 somatic chromosomes to detect DNA released from a patient's kidney allograft, known as donor-derived cell-free DNA (dd-cfDNA).

### What is cell-free DNA and donor derived cell-free DNA?

Cell-Free DNA is fragments of DNA in the bloodstream that originate from cells undergoing injury and death. Leveraging SNPs across 22 chromosomes, AlloSure can quantify increasing levels of dd-cfDNA, serving as a leading indicator of graft injury.




1. Bloom RD et al. J Am Soc Nephrol 2017; 28:2221–2232. The DART (DNA in Blood for Diagnosing Acute Kidney Rejection in Kidney Transplant Patients) trial was a prospective, multi-center study.



## Empowering Your Management of Kidney Transplant Patients

AlloSure's Data-Backed Scores Allow Clinicians to Understand Transplant Health



\*ABMR = Antibody-Mediated Rejection

\*\*DSA = Donor-Specific Antibodies

\*\*\*TCMR = T Cell-Mediated Rejection

\*\*\*\*NPV: Negative Predictive Value

2. Jordan SC et al. Transplant Direct 2018; 4:e379

3. Bloom RD et al. J Am Soc Nephrol 2017; 28:2221-2232

4. Stites E, et al. Am J Transplant. 2020; 00:1-8

5. Bloom RD et al. J Am Soc Nephrol 2017; 28:2221-2232

## AlloSure is a Broadly-Adopted and Clinically Validated Surveillance Tool

**14** 

Center  
Prospective  
Validation Trial

**1 in 3** 

Newly Transplanted  
Kidney Patients  
Receives AlloSure

**>150** 

Centers Actively  
Using AlloSure

**40+** 

Journal  
Publications



Covered  
by Medicare

For more information, visit [caredx.com/allosure](https://caredx.com/allosure)